Alkem Laboratories · tone and specificity signals across the available quarters.
Language signals
We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high potential non-US markets as well and capturing new opportunities that align with our long-term growth ambitions.
If the year progresses the way we are seeing for some more time then definitely we would overachieve on the guidance that we have given but at this stage I will stay with the guidance.
Tariff is a very hypothetical question... we will deal with it as and when it comes.
We'll continue to outperform the market at least by 100 to 150 basis points.
I see somewhere between 19 and a half to 20 should be our EBITDA for the full year.
We are hopeful that we should be closing the year close to a double digit kind of growth from US.
We crossed 3,000 crores. So it's been a fantastic year and I will let Vikas fill in more details.
In the most recent IQVIA report, we could garner a market unit market share of around 11%.
We have decided to move to the new tax regime from April 26 onwards. So the tax rate will be around 27 to 29% going forward.